188 related articles for article (PubMed ID: 33312423)
21. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
[TBL] [Abstract][Full Text] [Related]
22. A time-resolved, internally quenched fluorescence assay to characterize inhibition of hepatitis C virus nonstructural protein 3-4A protease at low enzyme concentrations.
Mao SS; DiMuzio J; McHale C; Burlein C; Olsen D; Carroll SS
Anal Biochem; 2008 Feb; 373(1):1-8. PubMed ID: 18022380
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A.
Vazquez C; Tan CY; Horner SM
J Virol; 2019 Dec; 93(23):. PubMed ID: 31534039
[TBL] [Abstract][Full Text] [Related]
24. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
Franco S; Clotet B; Martínez MA
Virus Res; 2008 Feb; 131(2):260-70. PubMed ID: 18037183
[TBL] [Abstract][Full Text] [Related]
25. Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors.
Geitmann M; Dahl G; Danielson UH
J Mol Recognit; 2011; 24(1):60-70. PubMed ID: 21194118
[TBL] [Abstract][Full Text] [Related]
26. Expression and purification of an active, full-length hepatitis C viral NS4A.
Back SH; Kim JE; Rho J; Hahm B; Lee TG; Kim EE; Cho JM; Jang SK
Protein Expr Purif; 2000 Nov; 20(2):196-206. PubMed ID: 11049744
[TBL] [Abstract][Full Text] [Related]
27. Selection of functional variants of the NS3-NS4A protease of hepatitis C virus by using chimeric sindbis viruses.
Filocamo G; Pacini L; Nardi C; Bartholomew L; Scaturro M; Delmastro P; Tramontano A; De Francesco R; Migliaccio G
J Virol; 1999 Jan; 73(1):561-75. PubMed ID: 9847361
[TBL] [Abstract][Full Text] [Related]
28. Comparative molecular dynamics simulation of Hepatitis C Virus NS3/4A protease (Genotypes 1b, 3a and 4b) predicts conformational instability of the catalytic triad in drug resistant strains.
Kramer M; Halleran D; Rahman M; Iqbal M; Anwar MI; Sabet S; Ackad E; Yousef MS
PLoS One; 2014; 9(8):e104425. PubMed ID: 25111232
[TBL] [Abstract][Full Text] [Related]
29. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
White PW; Llinàs-Brunet M; Amad M; Bethell RC; Bolger G; Cordingley MG; Duan J; Garneau M; Lagacé L; Thibeault D; Kukolj G
Antimicrob Agents Chemother; 2010 Nov; 54(11):4611-8. PubMed ID: 20823284
[TBL] [Abstract][Full Text] [Related]
30. Synthetic bulky NS4A peptide variants bind to and inhibit HCV NS3 protease.
El-Araby ME; Omar AM; Soror SH; Arold ST; Khayat MT; Asfour HZ; Bamane F; Elfaky MA
J Adv Res; 2020 Jul; 24():251-259. PubMed ID: 32373358
[TBL] [Abstract][Full Text] [Related]
31. Mechanistic role of NS4A and substrate in the activation of HCV NS3 protease.
Zhu H; Briggs JM
Proteins; 2011 Aug; 79(8):2428-43. PubMed ID: 21633972
[TBL] [Abstract][Full Text] [Related]
32. An uniquely purified HCV NS3 protease and NS4A(21-34) peptide form a highly active serine protease complex in peptide hydrolysis.
Sardana VV; Blue JT; Zugay-Murphy J; Sardana MK; Kuo LC
Protein Expr Purif; 1999 Aug; 16(3):440-7. PubMed ID: 10425166
[TBL] [Abstract][Full Text] [Related]
33. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.
Ren J; Ojeda I; Patel M; Johnson ME; Lee H
Bioorg Med Chem Lett; 2019 Aug; 29(16):2349-2353. PubMed ID: 31201062
[TBL] [Abstract][Full Text] [Related]
34. A novel recombinant single-chain hepatitis C virus NS3-NS4A protein with improved helicase activity.
Howe AY; Chase R; Taremi SS; Risano C; Beyer B; Malcolm B; Lau JY
Protein Sci; 1999 Jun; 8(6):1332-41. PubMed ID: 10386883
[TBL] [Abstract][Full Text] [Related]
35. Development and application of a fast, reproducible assay to measure HCV NS3 protease activity using Escherichia coli lysate.
Han B; Dvory-Sobol H; Greenstein A; McCarville JF; Hung M; Liu X; Miller MD; Mo H
J Virol Methods; 2015 Dec; 225():76-86. PubMed ID: 26391876
[TBL] [Abstract][Full Text] [Related]
36. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.
Asante-Appiah E; Curry S; McMonagle P; Ingravallo P; Chase R; Nickle D; Qiu P; Howe A; Lahser FC
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416549
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel.
Chatel-Chaix L; Baril M; Lamarre D
Viruses; 2010 Aug; 2(8):1752-1765. PubMed ID: 21994705
[TBL] [Abstract][Full Text] [Related]
38. A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target.
Schiering N; D'Arcy A; Villard F; Simic O; Kamke M; Monnet G; Hassiepen U; Svergun DI; Pulfer R; Eder J; Raman P; Bodendorf U
Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21052-6. PubMed ID: 22160684
[TBL] [Abstract][Full Text] [Related]
39. NS3-4A of hepatitis C virus is a chymotrypsin-like protease.
Hahm B; Han DS; Back SH; Song OK; Cho MJ; Kim CJ; Shimotohno K; Jang SK
J Virol; 1995 Apr; 69(4):2534-9. PubMed ID: 7884903
[TBL] [Abstract][Full Text] [Related]
40. Fluorescence resonance energy transfer-based assay for characterization of hepatitis C virus NS3-4A protease activity in live cells.
Sabariegos R; Picazo F; Domingo B; Franco S; Martinez MA; Llopis J
Antimicrob Agents Chemother; 2009 Feb; 53(2):728-34. PubMed ID: 19064890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
